- Gene therapy products are revolutionary treatments that involve altering the genes inside a patient's cells to treat or prevent disease. These products offer a promising solution for genetic disorders, cancers, and some viral infections, using techniques such as CRISPR-Cas9 and viral vector delivery systems
- The demand for gene therapy products is significantly driven by advancements in gene editing technologies, increasing investments in research and development, and the rising prevalence of genetic disorders such as sickle cell anaemia, Duchenne muscular dystrophy, and haemophilia
- North America is expected to dominate the global gene therapy products market due to its strong healthcare infrastructure, robust regulatory environment, and significant investments from both public and private sectors. The region also benefits from high adoption rates of cutting-edge technologies in medical treatments
- Asia-Pacific is expected to witness the fastest growth in the gene therapy products market during the forecast period. The increasing prevalence of genetic disorders, advancements in healthcare infrastructure, rising awareness about gene-based treatments, and improving regulatory frameworks in countries such as China and India are contributing to this rapid growth
- Oncological disorder segment is expected to dominate the market with a market share of 57.4% due to the increasing prevalence of various types of cancers worldwide and the growing adoption of gene therapy as a targeted treatment approach. Gene therapy's ability to specifically target cancer cells while minimizing damage to healthy cells has made it an increasingly attractive treatment option
